Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Emergent Biosolutions (NY: EBS )

8.240 +0.040 (+0.49%)
Official Closing Price Updated: 7:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,028,298
Open 8.350
Bid (Size) 8.120 (12)
Ask (Size) 8.610 (1)
Prev. Close 8.200
Today's Range 8.160 - 8.450
52wk Range 7.740 - 36.14
Shares Outstanding 50,400,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What 4 Analyst Ratings Have To Say About Emergent BioSolutions
 
Via Benzinga
Nasal-Spray Millionaire: Indivior's Opvee Nasal Spray Gets FDA Green Light for Opioid Overdose Treatment
The FDA has approved Indivior PLC's (OTC: INVVY) Opvee (nalmefene) nasal spray for the emergency treatment of opioid overdose in adults and pediatric patients aged 12 years and older. 
Via Benzinga

Performance

YTD
-31.45%
-31.45%
1 Month
-2.37%
-2.37%
3 Month
-29.33%
-29.33%
6 Month
-31.33%
-31.33%
1 Year
-74.86%
-74.86%

More News

Read More
Why Emergent BioSolutions Stock Inched Slightly Higher Today
Via The Motley Fool
Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT
From Emergent BioSolutions
Via GlobeNewswire
Recap: Emergent BioSolutions Q1 Earnings
Via Benzinga
Why Emergent BioSolutions Stock Is Soaring Today
Via The Motley Fool
FDA Approves First OTC Naloxone Nasal Spray For Opioid Overdose
Via Benzinga
Why Heron Therapeutics Shares Are Trading Lower By 34%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Emergent BioSolutions (EBS) Q1 2023 Earnings Call Transcript
Via The Motley Fool
Emergent BioSolutions Reports Financial Results For First Quarter 2023
From Emergent BioSolutions
Via GlobeNewswire
Emergent Plans $50 Price Point For Narcan OTC Version For Opioid Overdose Reversal
Via Benzinga
Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023
From Emergent BioSolutions
Via GlobeNewswire
CPI Sent Market Surging - But Some Stocks Took A Hit: Spotlight On Top Gainers And Hard-Hit Decliners
Via Benzinga
Tesla, Apple, Riot Platforms, AMC, Emergent Biosolutions: Why These 5 Stocks Are Drawing Investors' Attention Today
Via Benzinga
Emergent BioSolutions Soars: Analyst Upgrades Stock With Near 100% Upside After FDA's Positive Move
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 10, 2023
Via Benzinga
Micron Technology, Greenbrier Companies And Other Big Stocks Moving Higher On Monday
Via Benzinga
Why Bed Bath & Beyond Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Sprinklr, EVgo, Emergent BioSolutions And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Emergent Biosciences (EBS) Stock Pops as FDA Approves Over-the-Counter Narcan
Via InvestorPlace
FDA Approves Over The Counter Sale Of Opioid Reversal Drug Narcan
Via Benzinga
U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment
From Emergent BioSolutions
Via GlobeNewswire
Why Emergent Biosolutions Stock Is Surging Today
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.